Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study
<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...
Váldodahkkit: | Donovan, K, Herrington, W, Haynes, R, Sardell, R, Baigent, C, Holmes, M, Staplin, N |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
American Society of Nephrology
2022
|
Geahča maid
-
Fibroblast growth factor-23 and risks of cardiovascular and non-cardiovascular diseases: a meta-analysis
Dahkki: Marthi, A, et al.
Almmustuhtton: (2018) -
Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
Dahkki: Lamprea-Montealegre, J, et al.
Almmustuhtton: (2019) -
Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
Dahkki: Ying Liang, et al.
Almmustuhtton: (2021-07-01) -
Corrigendum: Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
Dahkki: Ying Liang, et al.
Almmustuhtton: (2021-11-01) -
Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients—Cardiologists Be Aware
Dahkki: Anna Kurpas, et al.
Almmustuhtton: (2022-05-01)